CD274 and non-small cell lung carcinoma: In NSCLC, METTL3-driven m6A methylation leads to the destabilization of PD-L1 mRNA, which reduces the therapeutic efficacy of anti-PD-1/PD-L1 interventions; however, the knockout of METTL3 increases immune cell infiltration and enhances the therapeutic efficacy of anti-PD-1/PD-L1 (122).